drug · small molecule
levacetylleucine
Marketedupdated 5mo agoby IntraBio Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for niemann-pick disease type c and 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying levacetylleucine
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 24, 2029
~3.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Apr 19, 2037method-of-use (U-4170)US 11400067
- Apr 19, 2037method-of-use (U-4284)US 12433862
- Apr 19, 2037method-of-use (U-4285)US 12433863
FDA exclusivities (2)
- Sep 24, 2031ODE-498Orphan Drug (7y)5.0y
- Sep 24, 2029NCENew Chemical Entity (5y)3.0y
News(1)
- FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD dataPlus news about Biokin, Bristol Myers Squibb, Grünenthal and Johnson & Johnson. FDA approves ataxia-telangiectasia treatment: The agency approved the rare genetic disease treatment Aqneursa from th…endpoints · 8d ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that